ATRA

ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, August 6, 2022 - 2:00am

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.
  • Our investigation concerns whether Atara has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On November 4, 2021, Atara issued a press release touting its T cell immunotherapy product candidate, ATA188.
  • In this release, the Company claimed that there was "positive momentum around the ATA188 program" and "increasing awareness of and excitement .

Bragar Eagel & Squire, P.C. Is Investigating TuSimple, Atara, Mercury, and the WWE and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, August 6, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • The article alleges that one of the Companys autonomously driven trucks left its lane of travel without warning before striking a cement barricade.
  • The article also reveals that the Federal Motor Carrier Safety Administration has launched a safety compliance investigation.
  • For more information on the WWE investigation go to: https://bespc.com/cases/WWE
    About Bragar Eagel & Squire, P.C.

ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, August 5, 2022 - 2:00am

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA) on behalf of Atara stockholders.
  • Our investigation concerns whether Atara has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On November 4, 2021, Atara issued a press release touting its T cell immunotherapy product candidate, ATA188.
  • In this release, the Company claimed that there was "positive momentum around the ATA188 program" and "increasing awareness of and excitement .

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, August 4, 2022 - 9:01pm

These awards were approved by the Compensation Committee of Ataras Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of August 1, 2022, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These awards were approved by the Compensation Committee of Ataras Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of August 1, 2022, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Atara Biotherapeutics, Inc. ( @Atarabio ) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.
  • Improving patients lives is our mission and we will never stop working to bring transformative therapies to those in need.
  • For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn .

Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

Retrieved on: 
Wednesday, August 3, 2022 - 9:01pm

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 9:00 a.m. PDT / 12:00 p.m. EDT.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 9:00 a.m. PDT / 12:00 p.m. EDT.
  • A live webcast of the presentation will be available by visiting the Investor Events and Presentations section of atarabio.com .
  • An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.
  • Atara Biotherapeutics, Inc. ( @Atarabio ) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.

Atara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022

Retrieved on: 
Monday, August 1, 2022 - 9:01pm

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2022 financial results after market close on Monday, August 8, 2022.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2022 financial results after market close on Monday, August 8, 2022.
  • Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Companys financial results and provide a corporate update.
  • Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID 13730293.
  • A live audio webcast can be accessed by visiting the Investors & Media News & Events section of atarabio.com .

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Atara Biotherapeutics, Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Thursday, July 28, 2022 - 10:18pm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ: ATRA ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • Atara issued a press release on July 12, 2022, updating the market on its preliminary analysis phase 2 EMBOLD study for product candidate ATA188.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

ATRA INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Atara Biotherapeutics, Inc.

Retrieved on: 
Wednesday, July 27, 2022 - 3:49pm

New York, New York--(Newsfile Corp. - July 27, 2022) - Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning possible violations of federal securities laws.

Key Points: 
  • New York, New York--(Newsfile Corp. - July 27, 2022) - Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) concerning possible violations of federal securities laws.
  • On November 4, 2021, Atara issued a press release touting its T cell immunotherapy product candidate, ATA188.
  • In this release, the Company claimed that there was "positive momentum around the ATA188 program" and "increasing awareness of and excitement .
  • Then, on February 28, 2022, Atara issued a press release attached to their Form 8-K, providing an update on ATA188.

Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS

Retrieved on: 
Tuesday, July 12, 2022 - 9:30pm

The IA was planned to occur before enrolling patient 80 to enable an increased sample size if needed.

Key Points: 
  • The IA was planned to occur before enrolling patient 80 to enable an increased sample size if needed.
  • The IDSMC believes the six-month interim endpoint may be an inaccurate measure of the potential of this intervention in this condition.
  • The IDSMC recommended continuing the study without sample size adjustment until the final analysis of the primary endpoint of confirmed EDSS improvement at 12 months.
  • Following the EMBOLD IA, we are proceeding with the IDSMCs recommendation that the study continue to completion without sample size adjustment, said Jakob Dupont, M.D., Head of Global Research & Development at Atara.

Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022

Retrieved on: 
Wednesday, July 6, 2022 - 9:01pm

Following the release, the Company will host a live conference call and webcast at 5:00 p.m. EDT.

Key Points: 
  • Following the release, the Company will host a live conference call and webcast at 5:00 p.m. EDT.
  • Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID 13731189.
  • A live audio webcast can be accessed by visiting the Investors & Media News & Events section of atarabio.com .
  • Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.